Neuroleptic Malignant Syndrome (NMS): Symptoms, Causes, Diagnosis, and Treatment

Neuroleptic Malignant Syndrome (NMS) is a rare but potentially fatal neurological emergency that occurs as an adverse reaction to medications that affect dopamine neurotransmission in the brain — most notably antipsychotic (neuroleptic) drugs. The syndrome is characterized by a distinctive tetrad of symptoms: severe muscle rigidity, high fever (hyperthermia), autonomic nervous system instability, and altered mental status ranging from confusion to coma.

NMS was first described in the medical literature in 1960 by French clinicians shortly after the introduction of haloperidol. Despite decades of clinical awareness, it remains a diagnostic challenge because its presentation can mimic other serious medical conditions and it can develop at any point during treatment — from the first dose of a medication to years into a stable regimen.

How common is NMS? Estimates of incidence vary, but most current literature places the rate at approximately 0.01% to 0.02% of individuals exposed to antipsychotic medications. Older studies reported higher rates (up to 3%), likely reflecting the more widespread use of high-potency first-generation antipsychotics and less clinical awareness. With the shift toward second-generation (atypical) antipsychotics and improved recognition, the incidence has declined — but NMS has not been eliminated. It can occur with virtually any dopamine-blocking or dopamine-depleting agent.

The mortality rate has also improved significantly over time. Historical mortality rates approached 30% or higher, but with early recognition and aggressive treatment, contemporary estimates place mortality at approximately 5% to 10%. However, delayed diagnosis or inadequate treatment still carries a substantial risk of death or lasting complications, making prompt identification essential.

NMS typically develops over a period of 24 to 72 hours, though onset can be more rapid or more insidious. The clinical presentation revolves around four cardinal features, often referred to as the classic tetrad:

• Severe muscular rigidity: Often described as "lead-pipe rigidity," this refers to a generalized, intense stiffness of the muscles that resists passive movement in all directions. This is typically the most prominent early finding and can be so severe that it impairs breathing.
• Hyperthermia (high fever): Body temperature often exceeds 38°C (100.4°F) and can climb above 40°C (104°F) in severe cases. This fever is not caused by infection but rather by the extreme metabolic demand of sustained muscle contraction and dysregulated thermoregulation.
• Autonomic instability: The autonomic nervous system — which controls involuntary functions like heart rate, blood pressure, and sweating — becomes profoundly dysregulated. Signs include rapid heart rate (tachycardia), labile or elevated blood pressure, excessive sweating (diaphoresis), urinary incontinence, and pallor.
• Altered mental status: This ranges from agitation, confusion, and delirium to obtundation (severely reduced alertness) and coma. Changes in consciousness are often among the earliest signs but can be mistakenly attributed to the underlying psychiatric condition.

Additional signs and symptoms may include:

• Tremor, which may be present alongside rigidity
• Dysphagia (difficulty swallowing) and dysarthria (slurred speech)
• Sialorrhea (excessive salivation)
• Mutism or catatonia-like features
• Elevated serum creatine kinase (CK) levels — often dramatically elevated, reflecting severe muscle breakdown (rhabdomyolysis)
• Leukocytosis (elevated white blood cell count) without evidence of infection

Early warning signs that should prompt immediate clinical concern include an unexpected onset of muscle stiffness, low-grade fever, unexplained tachycardia, or new-onset confusion in any patient taking a dopamine-blocking medication. These early indicators can progress rapidly to the full syndrome if the offending medication is not discontinued.

The central mechanism underlying NMS is believed to be a sudden, significant reduction in dopaminergic activity in the central nervous system, particularly in the hypothalamus (which regulates body temperature) and the basal ganglia (which regulate movement). This dopamine blockade triggers a cascade of downstream effects including muscle rigidity, hyperthermia, and autonomic dysfunction.

Medications most commonly associated with NMS include:

• First-generation (typical) antipsychotics: Haloperidol, chlorpromazine, and fluphenazine carry the highest risk historically. High-potency agents like haloperidol are more frequently implicated than low-potency agents.
• Second-generation (atypical) antipsychotics: Olanzapine, risperidone, quetiapine, aripiprazole, clozapine, and others have all been associated with NMS, though generally at lower rates. No atypical antipsychotic is considered completely free of risk.
• Antiemetics with dopamine-blocking properties: Metoclopramide and prochlorperazine are well-documented causes of NMS.
• Other dopamine-depleting agents: Tetrabenazine, used for movement disorders, has been implicated in rare cases.
• Abrupt withdrawal of dopaminergic medications: Sudden discontinuation of levodopa or dopamine agonists in patients with Parkinson's disease can trigger a syndrome clinically identical to NMS, sometimes called "neuroleptic malignant-like syndrome" or "parkinsonism-hyperpyrexia syndrome."

Risk factors that increase susceptibility include:

• Rapid dose escalation or high doses of antipsychotic medications
• Intramuscular (IM) administration of antipsychotics, which produces higher peak plasma levels
• Use of multiple neuroleptic agents concurrently
• Dehydration and physical exhaustion — these are among the most consistently identified modifiable risk factors
• Agitation or catatonia at the time of medication administration
• History of prior NMS episodes — recurrence rates in individuals re-exposed to antipsychotics range from approximately 15% to 30%
• Organic brain disease, intellectual disability, or concurrent medical illness
• Iron deficiency — low serum iron has been identified as a potential risk factor, possibly because iron is a cofactor for dopamine receptor function
• Male sex and younger age — some studies suggest a male-to-female ratio of approximately 2:1, though NMS occurs across all demographics

It is important to emphasize that NMS is not dose-dependent in a predictable way — it can occur with a single therapeutic dose in a susceptible individual, or after years on a stable regimen. This idiosyncratic nature means that individual vulnerability, possibly involving genetic factors related to dopamine receptor sensitivity, plays a significant role that is not yet fully understood.

There is no single definitive laboratory test or imaging study that confirms NMS. Diagnosis is fundamentally clinical — it relies on recognizing the characteristic pattern of symptoms in the context of recent exposure to a dopamine-blocking agent (or withdrawal of a dopaminergic agent) and systematically ruling out other conditions that can produce a similar picture.

Diagnostic criteria have been proposed by several expert groups. The DSM-5-TR includes Neuroleptic Malignant Syndrome as a medication-induced movement disorder (coded under "Other Adverse Effects of Medication") and identifies the core features of exposure to a dopamine-blocking agent, severe muscle rigidity, fever, and associated findings such as altered consciousness, autonomic instability, and elevated creatine kinase. However, the DSM-5-TR notes that not all features need to be present simultaneously, and the presentation can be incomplete or atypical, particularly with second-generation antipsychotics.

An influential set of diagnostic criteria proposed by an international expert consensus group requires:

• Recent exposure to a dopamine antagonist (or withdrawal of a dopamine agonist) within the past 72 hours
• Hyperthermia (>38°C / 100.4°F on at least two occasions)
• Rigidity
• Altered mental status
• Elevated creatine kinase (at least four times the upper limit of normal)
• Sympathetic nervous system lability (defined by at least two of: elevated blood pressure, tachycardia, diaphoresis, urinary incontinence)
• Exclusion of other causes (infections, toxins, metabolic or neurological conditions)

Laboratory findings that support the diagnosis include:

• Markedly elevated creatine kinase (CK): Often exceeding 1,000 IU/L and sometimes reaching tens of thousands, reflecting rhabdomyolysis
• Leukocytosis: White blood cell counts of 10,000–40,000/μL are typical
• Elevated liver transaminases and lactate dehydrogenase
• Metabolic acidosis with elevated lactate
• Low serum iron
• Myoglobinuria: Dark or cola-colored urine indicating muscle protein in the urine, a sign of rhabdomyolysis that can lead to acute kidney injury

Differential diagnosis is critical and includes serotonin syndrome (which features hyperreflexia and clonus rather than lead-pipe rigidity), malignant hyperthermia (triggered by anesthetic agents), lethal catatonia, central nervous system infections (meningitis, encephalitis), heatstroke, thyroid storm, and drug intoxication. Distinguishing NMS from these conditions requires careful clinical assessment, and sometimes the differentiation is difficult even for experienced clinicians.

NMS is a medical emergency that requires immediate hospitalization, typically in an intensive care unit. Treatment focuses on several simultaneous priorities:

1. Immediate discontinuation of the offending agent

The single most important intervention is stopping the causative medication immediately. If NMS was triggered by withdrawal of a dopaminergic medication (as in Parkinson's disease), that medication should be promptly reinstated. Every hour of delay in discontinuation increases the risk of complications and death.

2. Aggressive supportive care

• Cooling measures: External cooling (ice packs, cooling blankets, evaporative cooling) and, in severe cases, internal cooling methods (cold intravenous fluids, gastric lavage with cold saline) to reduce body temperature
• Intravenous hydration: Aggressive fluid resuscitation is essential to prevent acute kidney injury from rhabdomyolysis-associated myoglobinuria
• Monitoring: Continuous cardiac monitoring, blood pressure monitoring, urine output measurement, and serial laboratory assessments (CK, renal function, electrolytes, arterial blood gases)
• Thromboprophylaxis: Patients with prolonged immobility and rigidity are at high risk for deep vein thrombosis and pulmonary embolism
• Respiratory support: Mechanical ventilation may be necessary if rigidity compromises respiratory function or if consciousness is severely impaired

3. Pharmacological interventions

• Dantrolene sodium: A direct-acting skeletal muscle relaxant that works by inhibiting calcium release from the sarcoplasmic reticulum, thereby reducing muscle rigidity and the associated heat generation. It is administered intravenously, typically at 1–2.5 mg/kg, and can be repeated as needed. Dantrolene has the strongest evidence base of any pharmacological intervention for NMS, though randomized controlled trials are lacking due to the rarity and severity of the condition.
• Bromocriptine: A dopamine agonist that directly addresses the underlying dopaminergic deficit. It is administered orally or via nasogastric tube at doses of 2.5–5 mg two to three times daily. Some clinicians use bromocriptine and dantrolene in combination.
• Amantadine: Another dopaminergic agent that can be used as an alternative or adjunct to bromocriptine.
• Benzodiazepines: Lorazepam is frequently used to manage agitation, reduce muscle tone, and address catatonic features. Some experts consider benzodiazepines a first-line adjunctive treatment, particularly when the distinction between NMS and lethal catatonia is unclear.

4. Electroconvulsive therapy (ECT)

ECT has been used successfully in severe or refractory cases of NMS, particularly when catatonic features are prominent or when the syndrome does not respond to pharmacological interventions within 48–72 hours. Case series and case reports support its efficacy, but it is typically reserved for treatment-resistant presentations.

The duration of the acute episode with appropriate treatment is typically 7 to 14 days when caused by oral medications, but can extend to 2 to 4 weeks or longer when triggered by long-acting injectable (depot) antipsychotic formulations, because the drug persists in the body for a prolonged period.

With early recognition and aggressive treatment, the majority of individuals with NMS recover fully. As noted, contemporary mortality rates are estimated at 5% to 10%, a marked improvement from the 30%+ mortality seen in earlier decades. The most common causes of death are respiratory failure, cardiovascular collapse, renal failure secondary to rhabdomyolysis, disseminated intravascular coagulation (DIC), and sepsis from aspiration pneumonia or prolonged immobilization.

Potential complications during and after NMS include:

• Acute kidney injury from myoglobin-induced tubular necrosis (rhabdomyolysis)
• Aspiration pneumonia due to impaired swallowing and reduced consciousness
• Deep vein thrombosis and pulmonary embolism
• Disseminated intravascular coagulation (DIC)
• Persistent neurological deficits: Some patients experience residual cognitive impairment, cerebellar dysfunction, or peripheral neuropathy, particularly if the episode was prolonged or if hyperthermia was severe and sustained

Returning to antipsychotic treatment after NMS is one of the most clinically challenging decisions. Many individuals who develop NMS have serious psychiatric conditions — such as schizophrenia or bipolar disorder — that require ongoing pharmacological management. Expert recommendations generally include:

• Waiting at least two weeks after complete resolution of NMS before considering re-challenge with any antipsychotic
• Choosing a structurally dissimilar, lower-potency agent — preferably a second-generation antipsychotic from a different chemical class than the offending drug
• Starting at the lowest effective dose and titrating slowly
• Ensuring adequate hydration and avoiding concurrent risk factors (dehydration, agitation, polypharmacy)
• Close monitoring for early signs of recurrence, including regular vital sign checks and CK monitoring during the initial re-exposure period

The recurrence rate upon re-exposure to antipsychotic medication is estimated at 15% to 30% in some studies, though adherence to careful re-introduction protocols significantly reduces this risk.

Several conditions share clinical features with NMS and must be distinguished from it — both because they require different treatments and because misdiagnosis can be fatal.

Serotonin Syndrome

This potentially life-threatening condition results from excessive serotonergic activity, typically from drug interactions involving serotonergic medications (SSRIs, SNRIs, MAOIs, triptans, tramadol, and others). It shares features with NMS such as hyperthermia and altered mental status, but key differences include the presence of hyperreflexia, clonus (involuntary rhythmic muscle contractions), and myoclonus rather than the lead-pipe rigidity characteristic of NMS. Onset is typically more rapid (within hours of the triggering exposure), and the lower extremities are often more prominently affected.

Malignant Hyperthermia

This is a pharmacogenetic condition triggered by volatile anesthetic agents (e.g., halothane, sevoflurane) or the depolarizing neuromuscular blocker succinylcholine. It presents with extreme hyperthermia and rigidity in the perioperative setting. The underlying mechanism involves uncontrolled calcium release in skeletal muscle due to mutations in the ryanodine receptor gene. Treatment with dantrolene is highly effective and is the cornerstone of management.

Lethal (Malignant) Catatonia

This is perhaps the most difficult differential, as lethal catatonia shares virtually all features of NMS — rigidity, hyperthermia, autonomic instability, and altered consciousness. Some researchers have proposed that NMS may actually be a drug-induced form of lethal catatonia. The distinction is primarily contextual: lethal catatonia occurs in the absence of neuroleptic exposure and is associated with underlying psychiatric or medical conditions. Treatment includes benzodiazepines and ECT.

Other conditions in the differential include:

• Central nervous system infections (meningitis, encephalitis) — neuroimaging and lumbar puncture help distinguish these
• Heatstroke — environmental context and absence of rigidity help differentiate
• Thyroid storm — thyroid function tests are critical
• Pheochromocytoma crisis — characterized by paroxysmal hypertension and catecholamine excess
• Substance intoxication — particularly stimulants (cocaine, amphetamines) and phencyclidine (PCP), which can cause hyperthermia and rigidity
• Acute intermittent porphyria — can present with autonomic instability and altered mental status

NMS is a medical emergency. Unlike many psychiatric conditions where professional evaluation can be scheduled, NMS requires immediate emergency department evaluation — ideally calling emergency services (911 in the United States) at the first sign of concern.

Seek emergency medical attention immediately if someone taking an antipsychotic medication or any dopamine-blocking drug develops:

• Unexplained high fever, especially when accompanied by muscle stiffness
• Severe, generalized muscle rigidity that was not previously present
• Rapid heart rate, unstable blood pressure, or profuse sweating that is unexplained
• Sudden confusion, disorientation, or decreased responsiveness
• Dark-colored (cola-colored) urine, which may indicate rhabdomyolysis
• Any combination of the above symptoms, regardless of severity

Important considerations for patients, families, and caregivers:

• Do not wait for the full tetrad of symptoms to develop. Early or incomplete presentations are common, and early intervention saves lives.
• Inform emergency medical personnel about all medications the person is taking, including recent dose changes, newly started medications, and any recently discontinued medications.
• Do not stop antipsychotic medications on your own without medical guidance — but in a suspected NMS emergency, the medication will be discontinued by the treating medical team.
• If someone has a history of a prior NMS episode, this information should be clearly documented in their medical records and communicated to all treating providers.

Patients and families should also be aware that NMS can develop at any point during antipsychotic treatment — not just when starting a new medication. Vigilance for the early warning signs described above is warranted throughout the course of treatment.

For broader mental health concerns, including questions about antipsychotic medications and their side effects, consultation with a psychiatrist or other qualified mental health professional is recommended. The Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 1-800-662-4357 provides free, confidential referrals 24 hours a day, 7 days a week.